Navigation Links
Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference
Date:4/11/2008

ve different expression in various pathological conditions. As a result, these differences may provide for a novel diagnostic strategy for many diseases.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNA. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic and therapeutic tools, focusing primarily on cancer and various women's health indications. The company expects that the first microRNA diagnostic tests applying its technology will be launched by licensed clinical laboratories in the United States in 2008.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the role of microRNAs in human physiology and disease, the potential of microRNAs in the diagnosis and treatment of disease and the expected timing of submission for approval and launch of diagnostic tests using our microRNA technology constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover microRNA technology and to work on the application of thi
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
10. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
11. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... State Biotech Leaders to Develop Blueprint to ... while Boosting Rhode Island,s Growing Biotech and ... Dec. 14 Several of Rhode ... and biotechnology gathered today at Brown University,s ... of medical innovation in Rhode Island and ...
(Date:12/14/2009)... -- Lionbridge (Nasdaq: LIOX ) today ... three-year master services agreement with a multi-billion ... that serve patients in approximately 100 countries. ... sole provider for translation of the company,s ... human resources, legal, and corporate communications information. ...
(Date:12/14/2009)... a US-based thermoforming company, has completed the delivery of Brookfield ... metal to a plastic enclosure with a smaller footprint and ... ... MA (PRWEB) December 14, 2009 -- ThermoFab, a US-based thermoforming ... Tester – helping Brookfield move from sheet metal to a ...
(Date:12/11/2009)... Dec. 11 Dendreon Corporation (Nasdaq: ... its previously announced public offering have exercised in ... shares of common stock at the public offering ... of the option increases the size of the ... common stock. Dendreon expects to receive net ...
Breaking Biology Technology:Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 3Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 4Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement 2Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement 3Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3
... flexibility for placement in small, medium and ... ... Boston Scientific,Corporation (NYSE: BSX ) today announced CE Mark approval ... therapy,defibrillators and cardiac resynchronization therapy pacemakers, both of,which treat heart failure. ...
... Pennysylvania, March 3, Shire plc (LSE: SHP)(NASDAQ: ... Renovo Group plc, (LSE:,RNVO) ("Renovo") has today announced ... JUVISTA(R) (human recombinant TGFbeta3) in scar revision surgery,(RN1001-319-1009) ... release can be found on http://www.renovo.com ., ...
... France, March 3 NicOx S.A.,(Euronext Paris: COX) ... studies in the United States, which will assess ... ibuprofen and naproxen,using the Ambulatory Blood Pressure Monitoring ... in duration, will together recruit a,total of around ...
Other Biology Technology:Boston Scientific Announces European Approval of New Heart Failure Lead 2Boston Scientific Announces European Approval of New Heart Failure Lead 3Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3) 2Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3) 3NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 2NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 3NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 4NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 5
(Date:12/14/2009)... 14, 2009) -- Researchers at Rice University and Baylor ... that can be tracked in real time with MRI ... with a fluorescent dye and kills them with heat. ... from a growing field called "theranostics" that develops technologies ... a single procedure. , The research is available online ...
(Date:12/14/2009)... (BMES) have founded a new journal Cardiovascular Engineering ... is a forum for research on all aspects ... issue of the new quarterly journal will appear in ... Springer, Annals of Biomedical Engineering and ... and Technology will present a wide spectrum of ...
(Date:12/14/2009)... feature of humans. That,s until examples of tool use came ... of other mammals. Now, a report in the December 14th ... adds an octopus to the growing list of tool users. ... that the researchers call stilt walking. In it, the soft-bodied ... its eight arms rigid, and raises the whole assembly to ...
Breaking Biology News(10 mins):Tracking new cancer-killing particles with MRI 2Biomedical Engineering Society's new journal to be published by Springer 2Tool use in an invertebrate: The coconut-carrying octopus 2Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimers Disease 4733 1Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimers Disease 4733 2Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimers Disease 4733 3Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimers Disease 4733 4Blood Test Shows Statistically Significant Association With Alzheimers Disease 28AD 29 May Predict Conversion of Mild Cognitive Impairment to AD 51872 1Blood Test Shows Statistically Significant Association With Alzheimers Disease 28AD 29 May Predict Conversion of Mild Cognitive Impairment to AD 51872 2AstraZeneca and Mental Health Research Institute in Australia Announce Collaboration to Improve Early Detection of Alzheimers Disease 51870 1AstraZeneca and Mental Health Research Institute in Australia Announce Collaboration to Improve Early Detection of Alzheimers Disease 51870 2AstraZeneca and Mental Health Research Institute in Australia Announce Collaboration to Improve Early Detection of Alzheimers Disease 51870 3
... German . , Because of its toxicity and ... can no longer be used or produced in many countries. ... hydrocarbons, such as chloroform (trichloromethane, CHCl3), also produce CCl4 as ... of this unwanted substance? A team headed by Bert M. ...
... today called for Europe to invest more funds into the ... crucial role in the function of human cells and which ... diabetes to Alzheimer,s. , Common lipids such as cholesterol are ... of cells and tissues, but human cells contain thousands of ...
... June 16, 2008 -- VaxInnate Corporation announced today that it ... pandemic influenza vaccines during BIO 2008 here this week. ... three BIO 2008 panel discussions: , On Tuesday, ... Preparing for the Next Pandemic," , 8:15-9:45 am in Room ...
Other Biology News:Fair trade 2Europe-wide investment in lipid research will help tackle disease, says new report 2VaxInnate to discuss seasonal and pandemic flu vaccines during BIO 2008 this week 2
... Streptavidin Sepharose High Performance, 5 ... media used in HiTrap Streptavidin columns ... compounds.Ideal for packing into Tricorn 5/50 ... when larger scale purifications are required.Extremely ...
...
...
...
Biology Products: